Vanguard Group Inc Clarus Therapeutics Holdings, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
Call Options
0 transactions
Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
---|
About Clarus Therapeutics Holdings, Inc.
- Ticker CRXT
- Exchange NASDAQ
- Shares Outstandng 52,020,700
- Market Cap $652
- Description
- Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for pr...